KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma
Kawazoe, A., Rha, S. Y., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yanez Weber, P. E., Wyrwicz, L., Shen, L., Ostapenko, Y., Bilici, M., Chung, H. C. C., Shitara, K., Mahave, M., Van Cutsem, E., Tabernero, J., Xu, L., Indellicati, G., Hatogai, K., & Janjigian, Y. Y. (2026). KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology, 44(16_suppl), 4040-4040. https://doi.org/10.1200/JCO.2026.44.16_suppl.4040 (Meeting abstract)
Deixa un comentari